9459 documents

Read All
19:31 , Feb 22, 2019 |  BC Extra  |  Company News

Indian generics champion Shah passes away

Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, passed away Friday. The trade group's associate secretary-general, Archana Jatkar, confirmed the news to BioCentury. Known in the industry as DG Shah, the executive was CEO of...
Read More
18:58 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Feb....
Read More
21:58 , Feb 21, 2019 |  BC Extra  |  Preclinical News

Repurposing an HIV target could aid brain injury recovery

Extending CCR5 inhibition beyond treating HIV/AIDS, UCLA researchers showed that blocking CCR5 could promote recovery from stroke and traumatic brain injury (TBI). CC chemokine receptor 5 (CCR5; CD195) is well known for its role in...
Read More
22:49 , Feb 20, 2019 |  BC Extra  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Tuesday...
Read More
16:13 , Feb 20, 2019 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: Transgenics and knockouts; pharmacokinetics/pharmacodynamics Rats expressing human UGT2 or CYP3A gene clusters could be used to predict the PK of drug compounds metabolized by the two enzyme families. Rats engineered to express the entire...
Read More
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
Read More
00:49 , Feb 16, 2019 |  BioCentury  |  Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

NodThera Ltd. is tackling both the inflammation and fibrosis that drive NASH by inhibiting the NLRP3 inflammasome, a target few companies have interrogated for the indication. With a £28 million ($37 million) series A led...
Read More
00:45 , Feb 16, 2019 |  BioCentury  |  Product Development

Embedding digital in Lilly’s portfolio

In its newly created position of chief digital officer, Eli Lilly and Co. is avoiding the rush to an all-out, all-encompassing role, instead circumscribing the focus to tools that improve patient outcomes and reduce total...
Read More
19:49 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the...
Read More
19:42 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Priority Review for Keytruda in RCC, head and neck cancer

FDA accepted and granted Priority Review to two sBLAs for anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK). The agency assigned a June 10 PDUFA date to an sBLA for Keytruda as a...
Read More